{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-23-000020","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.727575+00:00","generated_at":"2026-06-08T03:56:53.264526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MoonLake Q3 cash $496M; positive Phase 2 data for sonelokimab in HS and PsA","bullets":["Cash & equivalents $496.0M at Sept 30, 2023, expected to fund Phase 3 programs and regulatory filings.","Positive full 24-week data from Phase 2 MIRA trial in hidradenitis suppurativa announced.","Landmark 12-week data from Phase 2 ARGO trial in psoriatic arthritis presented.","R&D expenses $7.6M in Q3 (down from $8.7M Q2); G&A expenses $5.4M (up from $4.5M).","Phase 3 initiation targeted for 2024; End of Phase 2 FDA meeting in December 2023; 24-week ARGO data expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-23-000020","json":"https://secwatch.observer/filing/0001821586-23-000020.json","markdown":"https://secwatch.observer/filing/0001821586-23-000020.md","text":"https://secwatch.observer/filing/0001821586-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/0001821586-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/mnlk-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:56:53.264526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a56567a99bd9fea3dedc5f021e849d31ad115e2","claim":"MoonLake Immunotherapeutics reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000182158623000020/0001821586-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}